Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
PACRG Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q96M98 |
|---|---|
| Clone Names | 100712026 |
| Gene ID | 135138 |
|---|---|
| Other Names | Parkin coregulated gene protein, Molecular chaperone/chaperonin-binding protein, PARK2 coregulated gene protein, PACRG, GLUP |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | PACRG |
|---|---|
| Synonyms | GLUP |
| Function | Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (PubMed:36191189). Suppresses cell death induced by accumulation of unfolded Pael receptor (Pael-R, a substrate of Parkin). Facilitates the formation of inclusions consisting of Pael-R, molecular chaperones, protein degradation molecules and itself when proteasome is inhibited. May play an important role in the formation of Lewy bodies and protection of dopaminergic neurons against Parkinson disease (PubMed:14532270). |
| Cellular Location | Cytoplasm, cytoskeleton, cilium axoneme |
| Tissue Location | Expressed in all immune tissues, spleen, lymph nodes, thymus, tonsils, leukocyte and bone marrow. Expressed also in heart, brain, skeletal muscle, kidney, lung and pancreas. Expressed in primary Schwann cells and very weakly by monocyte-derived macrophages the primary host cells of Mycobacterium leprae, the causative agent of leprosy. Component of Lewy bodies, intraneuronal inclusions found in the brain of Parkinson disease patients. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a protein that is conserved acrossmetazoans. In vertebrates, this gene is linked in a head-to-headarrangement with the adjacent parkin gene, which is associated withautosomal recessive juvenile Parkinson's disease. These genes areco-regulated in various tissues and they share a bi-directionalpromoter. Both genes are associated with susceptibility to leprosy.The parkin co-regulated gene protein forms a large molecularcomplex with chaperones, including heat shock proteins 70 and 90,and chaperonin components. This protein is also a component of Lewybodies in Parkinson's disease patients, and it suppresses unfoldedPael receptor-induced neuronal cell death. Multiple transcriptvariants encoding different isoforms have been found for this gene.
References
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Wilson, G.R., et al. Fertil. Steril. 93(7):2262-2268(2010)Dagda, R.K., et al. J. Bioenerg. Biomembr. 41(6):473-479(2009)Velez, D.R., et al. Int. J. Tuberc. Lung Dis. 13(9):1068-1076(2009)Taylor, J.M., et al. Parkinsonism Relat. Disord. 15(6):417-421(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
